Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The peritoneal cancer index as a predictor of complete cytoreduction at primary and interval cytoreductive surgery in advanced ovarian cancer.
Fagan PJ, Gomes N, Heath OM, Chandrasekaran D, Yao SE, Satchwell L, George A, Banerjee S, Sohaib A, Barton DP, Nobbenhuis M, Ind T, Butler J. Fagan PJ, et al. Among authors: chandrasekaran d. Int J Gynecol Cancer. 2023 Nov 6;33(11):1757-1763. doi: 10.1136/ijgc-2022-004093. Int J Gynecol Cancer. 2023. PMID: 37890875
Patient outcomes following interval and delayed cytoreductive surgery in advanced ovarian cancer: protocol for a multicenter, international, cohort study (Global Gynaecological Oncology Surgical Outcomes Collaborative).
Gaba F, Ash K, Blyuss O, Bizzarri N, Kamfwa P, Ramirez PT, Kotsopoulos IC, Chandrasekaran D, Gomes N, Butler J, Nobbenhuis M, Ind T, Heath O, Barton D, Jeyarajah A, Brockbank E, Lawrence A, Dilley J, Manchanda R, Phadnis S, Soar GO. Gaba F, et al. Among authors: chandrasekaran d. Int J Gynecol Cancer. 2022 Dec 5;32(12):1606-1610. doi: 10.1136/ijgc-2022-004101. Int J Gynecol Cancer. 2022. PMID: 36379595
Prognosis Following Surgery for Recurrent Ovarian Cancer and Diagnostic Criteria Predictive of Cytoreduction Success: A Systematic Review and Meta-Analysis.
Gaba F, Blyuss O, Chandrasekaran D, Bizzarri N, Refky B, Barton D, Ind T, Nobbenhuis M, Butler J, Heath O, Jeyarajah A, Brockbank E, Lawrence A, Manchanda R, Dilley J, Phadnis S, On Behalf Of The Go Soar Collaborative. Gaba F, et al. Among authors: chandrasekaran d. Diagnostics (Basel). 2023 Nov 20;13(22):3484. doi: 10.3390/diagnostics13223484. Diagnostics (Basel). 2023. PMID: 37998621 Free PMC article. Review.
Should Opportunistic Bilateral Salpingectomy (OBS) for Prevention of Ovarian Cancer Be Incorporated Into Routine Care or Offered in the Context of a Clinical Trial?
Manchanda R, Chandrasekaran D, Saridogan E, Burnell M, Crawford R, Brockbank E, Kalsi J, Jurkovic D, Menon U. Manchanda R, et al. Among authors: chandrasekaran d. Int J Gynecol Cancer. 2016 Jan;26(1):31-3. doi: 10.1097/IGC.0000000000000567. Int J Gynecol Cancer. 2016. PMID: 26658362 No abstract available.
Population Study of Ovarian Cancer Risk Prediction for Targeted Screening and Prevention.
Gaba F, Blyuss O, Liu X, Goyal S, Lahoti N, Chandrasekaran D, Kurzer M, Kalsi J, Sanderson S, Lanceley A, Ahmed M, Side L, Gentry-Maharaj A, Wallis Y, Wallace A, Waller J, Luccarini C, Yang X, Dennis J, Dunning A, Lee A, Antoniou AC, Legood R, Menon U, Jacobs I, Manchanda R. Gaba F, et al. Among authors: chandrasekaran d. Cancers (Basel). 2020 May 15;12(5):1241. doi: 10.3390/cancers12051241. Cancers (Basel). 2020. PMID: 32429029 Free PMC article.
Patient decision aids in mainstreaming genetic testing for women with ovarian cancer: A prospective cohort study.
Sobocan M, Chandrasekaran D, Sideris M, Blyuss O, Fierheller C, Kalra A, Sia J, Miller RE, Mills-Baldock T, Crusz SM, Sun L, Evans O, Robbani S, Jenkins LA, Ahmed M, Kumar A, Quigley M, Lockley M, Faruqi A, Casey L, Brockbank E, Phadnis S, Trevisan G, Singh N, Legood R, Manchanda R. Sobocan M, et al. Among authors: chandrasekaran d. BJOG. 2024 May;131(6):848-857. doi: 10.1111/1471-0528.17675. Epub 2023 Sep 26. BJOG. 2024. PMID: 37752678
Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer.
Manchanda R, Sun L, Sobocan M, Rodriguez IV, Wei X, Kalra A, Oxley S, Sideris M, Fierheller CT, Morgan RD, Chandrasekaran D, Rust K, Spiliopoulou P, Miller RE, Crusz SM, Lockley M, Singh N, Faruqi A, Casey L, Brockbank E, Phadnis S, Mills-Baldock T, El-Khouly F, Jenkins LA, Wallace A, Ahmed M, Kumar A, Swisher EM, Gourley C, Norquist BM, Evans DG, Legood R. Manchanda R, et al. Among authors: chandrasekaran d. J Natl Compr Canc Netw. 2024 Apr 18;22(2 D):e237331. doi: 10.6004/jnccn.2023.7331. J Natl Compr Canc Netw. 2024. PMID: 38866043
80 results